Aggressive lymphoma: news on ASH 2014
This article reviews the most important news at American Society of Hematology (ASH) 2014 for the clinician. A validated risk model for central nervous system (CNS) relapse after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) defined a low, intermediate, and a high risk group. The latter with a CNS-relapse risk of 12 %. Interim positron emission tomography (PET) imaging and different treatment strategies for positive disease were highly prognostic for an unfavorable prognosis. However, the salvage strategies for these patients were not successful. The role of radiotherapy was clarified in a randomized trial of non-bulky stage I or II disease. It was not possible to demonstrate an event-free (EFS) and overall (OS) survival benefit for radiation after 4–6 R-CHOP cycles. Unfortunately ofatumomab was not superior to rituximab in combination with DHAP in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
ConclusionsMYC rearrangements in DLBCL have no influence on the visual parameter necrosisPET or the semi-quantiative parameters SUVmax, MATV and TLG. Irrespective ofMYC rearrangements, necrosisPET is an independent, adverse prognostic factor for DSS.Key Points• Retrospective analysis indicates that MYC rearrangement is not associated with necrosis on18F-FDG PET (necrosisPET) scans or semiquantitative18F-FDG PET parameters.• NecrosisPETis a potential independent adverse prognostic factor for disease-specific survival in patients with DLBCL and is not influenced by the presence of MYC rearrangements.
ConclusionMTV and TLG reflecting the metabolic tumor burden can predict OS in patients with advanced lung adenocarcinoma.ResumenObjetivoEl presente estudio evalúa el valor pronóstico de los parámetros metabólicos relacionados con el tumor primario en el 18F-FDG PET/TC pretratamiento en pacientes con adenocarcinoma pulmonar en fase avanzada.Materiales y métodosEste estudio retrospectivo incluyó 258 pacientes con adenocarcinoma pulmonar en fase avanzada a los que se les realizó un escáner PET/TC del pretratamiento y para quienes estaba disponible el receptor del factor ...
ConclusionsDevelopment of WMC in PCNSL patients treated with MTX and MTX-R is common. WMC changes appear to be more frequent, occur earlier and are more extensive in patients treated with HD-MTX-R compared to HD-MTX. Prospective studies are required to determine whether WMC correlate with survival or neurocognitive outcomes.
CONCLUSION: A multivariate prediction model created using blood flow, vascular permeability, and glycometabolism parameters can predict the extent of hypoxia in FMISO-positive areas in patients with brain tumors. PMID: 31611541 [PubMed - as supplied by publisher]
In conclusion, pre-treatment PET scan has prognostic and predictive value in patients with advanced stage FL receiving frontline treatment. PMID: 31601688 [PubMed - as supplied by publisher]
Abstract13N-Ammonia (13N-NH3) is widely used positron emission tomography/computed tomography (PET/CT) radiotracer for the measurement of myocardial blood perfusion; the possible role of13N-NH3 PET or PET/CT in oncological disease is not yet clear. Aim of this review is to evaluate the diagnostic performances of13N-NH3 PET in this field. A comprehensive computer literature search of the PubMed/MEDLINE, Scopus, and Embase databases was conducted including articles up to June 2019. Eighteen articles were finally included in the review. From the analyses of the selected studies, the following main findings could be drawn: (1)...
ConclusionAll the characteristics of the work should alert the radiologist to consider lymphoma among the possible differential diagnoses, always correlating the results of the CT examination with appropriate clinical laboratory evaluations.
ConclusionsThis pilot study showed the potential of radiomics to distinguish GIST from other GI tumors, but no potential in predicting c-KIT mutational status and mitotic index of GISTs. Further optimization and validation of the radiomics model is required to incorporate radiomics in the diagnostic routine of GISTs.AcknowledgementM.J. Timbergen and M.P.A. Starmans contributed equally to this study.Legal entity responsible for the studyThe authors.FundingThe Netherlands Organization for Scientific Research.DisclosureAll authors have declared no conflicts of interest.
ConclusionsOutcome of patients with first-line H.pylori eradication failure followed by delayed chemotherapy and/or radiotherapy on indication was excellent.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
ConclusionsA substantial proportion of patients withH.pylori-negative gastric MALT lymphoma remain antibiotic-responsive and can be cured using radiotherapy and chemotherapy.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.